In a research note issued to investors, Joseph Pantginis at Roth Capital Reiterated their Buy rating on Argos Therapeutics Inc (NASDAQ:ARGS). The analyst placed a $21.00 price target on the stock which indicates a 166.50% upside to the last closing price. In the year following Joseph’s ratings, the stocks covered yield an average return of 7.2% according to TipRanks.com. In the past year 152 out of 308 recommendations or 49% were successful.
Wall Street analysts have placed a target price of $19 for Argos Therapeutics, Inc. (NASDAQ:ARGS). This number is based on the mean consensus estimate from the 3 research firms that recently issued reports on the stock.
The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 1 based on 3 broker recommendations. Of the 3 analysts who have issued estimates, the most bullish sees the stock reaching $21 within the next 12 months while the most conservative sees the stock at $16 within the year.
According to analysts, Argos Therapeutics, Inc. (NASDAQ:ARGS) is expected to report earnings per share for the current fiscal quarter of $-0.72. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.89. The reported number was -0.08 away from the consensus estimate, or a surprise factor of -9.88 .
In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.